CRISPR/Cas9-gene-editing therapeutics (Casebia Therapeutics)

N/A

Report date: 2025/03/19 08:59:20

Base Information

Drug NameCRISPR/Cas9-gene-editing therapeutics (Casebia Therapeutics)
Drug Alias NameN/A
ClassificationBiologicsCell and gene therapy > Cell therapy
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsGenetic Diseases, Inborn
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesCasebia Therapeutics Llc
China Registration ClassN/A

Develop Information

Active CompaniesCasebia Therapeutics Llc
Inactive CompaniesN/A
Active IndicationsGenetic Diseases, Inborn
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A